CN110870402A - Prescription for treating pneumonia infected by novel coronavirus and application thereof - Google Patents

Prescription for treating pneumonia infected by novel coronavirus and application thereof Download PDF

Info

Publication number
CN110870402A
CN110870402A CN202010081961.5A CN202010081961A CN110870402A CN 110870402 A CN110870402 A CN 110870402A CN 202010081961 A CN202010081961 A CN 202010081961A CN 110870402 A CN110870402 A CN 110870402A
Authority
CN
China
Prior art keywords
parts
prescription
ginger
gypsum
novel coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010081961.5A
Other languages
Chinese (zh)
Other versions
CN110870402B (en
Inventor
葛又文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202010081961.5A priority Critical patent/CN110870402B/en
Publication of CN110870402A publication Critical patent/CN110870402A/en
Application granted granted Critical
Publication of CN110870402B publication Critical patent/CN110870402B/en
Priority to JP2022546454A priority patent/JP7424684B2/en
Priority to CA3168659A priority patent/CA3168659A1/en
Priority to KR1020227028314A priority patent/KR20220137663A/en
Priority to PCT/CN2021/073829 priority patent/WO2021155751A1/en
Priority to TW110103119A priority patent/TWI792162B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a traditional Chinese medicine composition, and particularly discloses a prescription for treating pneumonia caused by novel coronavirus infection and application thereof. The raw materials of the prescription comprise the following traditional Chinese medicine materials in parts by weight: 9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb. The invention combines the pneumonia symptom expression of the novel coronavirus (2019-nCoV) infection, optimizes and fuses the traditional Chinese medicine formula, and treats the pneumonia together. From the prior treatment conditions of patients with confirmed diagnosis at different ages, a plurality of provinces and a plurality of places, the curative effect is definite, and the effective rate of the treatment reaches 95.12 percent.

Description

Prescription for treating pneumonia infected by novel coronavirus and application thereof
Technical Field
The invention relates to a traditional Chinese medicine composition, in particular to a prescription for treating pneumonia infected by novel coronavirus.
Background
2019A novel coronavirus, temporarily named 2019-nCoV coronavirus, is a new strain of coronavirus found in human in 2019. The symptoms of the virus are fever, hypodynamia, dry cough and gradual dyspnea, and severe patients show acute respiratory distress syndrome, septic shock, metabolic acidosis and blood coagulation dysfunction which are difficult to correct. The virus is confirmed to have a phenomenon of human transmission, the latent period is infectious, and no specific treatment method is provided for the diseases caused by the infectious latent period.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide a prescription (lung-clearing and toxin-expelling decoction) for treating pneumonia infected by novel coronavirus and application thereof.
In order to realize the purpose of the invention, the technical scheme of the invention is as follows:
in a first aspect, the invention provides a prescription for treating pneumonia infected by a novel coronavirus, which comprises the following Chinese medicinal materials in parts by weight:
8-10 parts of ephedra, 5-8 parts of honey-fried licorice root, 8-10 parts of almond, 15-30 parts of gypsum, 8-10 parts of cassia twig, 8-10 parts of rhizoma alismatis, 8-10 parts of polyporus umbellatus, 8-10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 15-18 parts of radix bupleuri, 5-8 parts of scutellaria baicalensis, 8-10 parts of ginger processed pinellia tuber, 8-10 parts of ginger, 8-10 parts of aster, 8-10 parts of flos farfarae, 8-10 parts of blackberry lily, 5-8 parts of asarum, 10-14 parts of Chinese yam, 5-8 parts of immature bitter orange, 5-8 parts of dried orange peel and 8-10 parts of wrinkled gianthys.
Preferably, the raw materials of the prescription comprise the following traditional Chinese medicine materials in parts by weight: 9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
The prescription of the invention refers to the Shang Zhong Jing (treatise on exogenous febrile diseases) of the classic Han Dynasty of traditional Chinese medicine, and is prepared from ephedra, almond, licorice and gypsum decoction (short for Ma xing Shi Gao decoction, Shang Han Lun 63), Xiao Chaihu decoction (Shang Han Lun 96), Wu Ling san (Shang Han Lun 71) and blackberry lily and ephedra decoction (Jinkui Yao, lung atrophy, lung carbuncle and cough upper qi syndrome treatment seventh) by reducing and cutting. The Chinese yam, the immature bitter orange, the dried orange peel and the wrinkled giant hyssop in the prescription are added and subtracted aiming at the clinical symptoms of the pneumonia infected by the novel coronavirus.
Wherein the Maxingshigan decoction has the effects of ventilating lung and expelling pathogenic factors; the five-poria cocos disperses dampness-resolving and turbid-dispelling herbs, promotes the three-warmer and removes dampness from urine, so that the dampness is removed from pores and urine; minor bupleurum soup carding minor yang machine; the blackberry lily and ephedra decoction has the effects of relieving exterior syndrome, resolving fluid retention, depressing qi and relieving cough; the wrinkled gianthyssop herb, the immature bitter orange and the dried orange peel regulate qi activity of spleen and stomach, and move qi and dissolve turbidity with fragrance, so that turbid qi in chest and abdomen is removed and breath is smooth; in addition, yam can tonify spleen and kidney, and strengthen healthy qi. The whole formula has the effects of clearing damp and dissolving turbidity, clearing lung and expelling pathogenic factors and harmonizing qi activity.
Further preferably, the traditional Chinese medicine raw materials of the prescription consist of the following traditional Chinese medicine materials in parts by weight:
9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
Wherein the dosage of the gypsum is adjusted according to whether the patient has fever or not, if the patient does not have fever, the dosage of the gypsum is small, and if the patient has fever or high fever, the dosage of the gypsum is increased.
Furthermore, the formulation is a decoction.
In a second aspect, the invention provides a process for the preparation of said formulation: decocting the above materials with water, wherein Gypsum Fibrosum is decocted first, and then other Chinese medicinal materials (decoction pieces of Chinese medicinal materials) are added and decocted.
In a third aspect, the invention provides application of the prescription (lung-clearing and toxin-expelling decoction) in preparation of a medicine with a lung-clearing and toxin-expelling efficacy.
And the application of the prescription (lung-heat clearing and toxin expelling decoction) in preparing the medicine for treating the pneumonia diseases.
In particular, the pneumonia is pneumonia caused by a viral infection.
The viruses include, but are not limited to, novel coronavirus 2019-nCoV, respiratory syndrome coronavirus, and respiratory syncytial virus.
Objective experiments prove that the prescription disclosed by the invention has a good treatment effect on pneumonia caused by the infection of the novel coronavirus 2019-nCoV.
As a recommendation, the use method of the prescription is as follows: decoct the drugs with water, take them one dose a day, twice in the morning and at night (forty minutes after meal), and warm. If the condition is met, half bowl of rice soup is taken after each dose of the medicine, and more than one bowl of rice soup can be taken for patients with dry tongue and fluid deficiency. Three treatment courses are provided. The patients are advised to take the medicine for a treatment course according to the original prescription, and the patients take the medicine for a second treatment course if the symptoms are good and the patients are not cured. If the patient has special conditions or other basic diseases, the prescription can be modified according to the actual conditions in the second treatment course, and the medicine is stopped when the symptoms disappear.
In addition, if constipation occurs before taking the formula, Fangfeng Tongsheng Wan should be added, and the pill should be stopped after defecation is smooth.
The raw materials or reagents involved in the invention are all common commercial products, and the operations involved are all routine operations in the field unless otherwise specified.
The above-described preferred conditions may be combined with each other to obtain a specific embodiment, in accordance with common knowledge in the art.
The invention has the beneficial effects that:
the invention combines epidemic disease symptom expression of the novel coronavirus pneumonia, and considers that the pneumonia infected by the novel coronavirus (2019-nCoV) belongs to the field of cold plague in the traditional Chinese medicine, and dampness pathogen is exuberant. The primary location of the disease is in the lung, and the secondary location of the disease is in the exterior, defense, spleen and stomach; the main diseases are caused by the intermingled pathogenic factors of dryness and damp-cold. The main pathogenesis is the damp-cold of epidemic toxin and the accumulation of latent dryness, which causes the obstruction of qi movement and the abnormal ascending and descending.
The invention provides the prescription, and various traditional Chinese medicines are optimized and fused to be applied together. The curative effect is exact according to the current curing conditions of patients with confirmed diagnosis at different ages. Relevant clinical observations studies are ongoing.
The prescription (lung-clearing and toxin-expelling decoction) provided by the invention is used by the emergency scientific research special item of the State administration of traditional Chinese medicine, namely 'effective prescription clinical screening research on preventing and treating novel coronavirus infection in traditional Chinese medicine', clinical observation work is carried out by combining clinical treatment at present, and related research is continuously promoted. The prescription is suitable for light, common and heavy patients, can be reasonably used by combining the actual conditions of the patients in the treatment of the critically ill patients, and has good social benefits.
Detailed Description
Preferred embodiments of the present invention will be described in detail with reference to the following examples. It is to be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the present invention. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the spirit and scope of this invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1
This example is used to illustrate the preparation method of the formulation (lung-heat clearing and toxin expelling decoction) of the present invention.
Firstly, raw materials (in parts by weight):
9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
Wherein the dosage of the gypsum is adjusted according to whether the patient has fever or not within the dosage range, if the patient does not have fever, the dosage of the gypsum is small, and if the patient has fever or high fever, the dosage of the gypsum is large.
Second, the preparation method
Weighing the raw materials (Chinese herbal pieces) according to the weight ratio, putting the gypsum into water for decoction, and putting other raw materials (Chinese herbal pieces) into the water for decoction.
After the decoction is finished, the prescription (lung clearing and toxin expelling decoction) of the invention is obtained.
Experimental example 1
The prescription (lung-clearing and toxin-expelling decoction) prepared in example 1 was administered to the confirmed cases of pneumonia infected with the novel coronavirus.
Decoct the drugs with water, take them one dose a day, twice in the morning and at night (forty minutes after meal), and warm. If the condition is met, half bowl of rice soup is taken after each dose of the medicine, and more than one bowl of rice soup can be taken for patients with dry tongue and fluid deficiency. Three treatment courses are provided.
By 2 months and 5 days, the prescription is used in 246 novel pneumonia confirmed cases infected by coronavirus in 37 hospitals in 36 cities of four provinces, and comprehensive observation is carried out on symptoms of hypodynamia, fever, cough, pharyngalgia, anorexia, imaging and the like, and data show that:
234 patients are effective after taking the medicine, and the total effective rate is about 95.12 percent. Wherein, after 81 patients take the medicine, the symptoms are stable and not aggravated, and account for about 32.93 percent of the total observed cases; 119 patients had improved symptoms, accounting for approximately 48.37% of the total observed cases; symptoms of 24 patients disappeared, accounting for about 9.76% of total observed cases; 10 patients were released from quarantine or discharge and accounted for approximately 4.07% of the total observed cases.
There were 12 patients (4.88%) whose disease continued to progress.
Example 2
This example differs from example 1 in that:
raw materials (in parts by weight):
8 parts of ephedra, 7 parts of honey-fried licorice root, 10 parts of almond, 15-30 parts of gypsum, 8 parts of cassia twig, 10 parts of rhizoma alismatis, 10 parts of grifola, 8 parts of bighead atractylodes rhizome, 14 parts of poria cocos, 15 parts of radix bupleuri, 7 parts of scutellaria baicalensis, 10 parts of ginger processed pinellia tuber, 8 parts of ginger, 10 parts of aster, 8 parts of flos farae, 10 parts of blackberry lily, 5 parts of asarum, 13 parts of Chinese yam, 5 parts of immature bitter orange, 7 parts of dried orange peel and 10 parts of wrinkled gianthyssop herb.
Example 3
This example differs from example 1 in that:
raw materials (in parts by weight):
10 parts of ephedra, 6 parts of honey-fried licorice root, 8 parts of almond, 15-30 parts of gypsum, 10 parts of cassia twig, 8 parts of rhizoma alismatis, 8 parts of grifola, 10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 8 parts of aster, 9 parts of flos farae, 10 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 5 parts of dried orange peel and 8 parts of wrinkled gianthyssop herb.
Example 4
This example differs from example 1 in that:
raw materials (in parts by weight):
9 parts of ephedra, 6 parts of honey-fried licorice root, 10 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 10 parts of grifola, 10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 8 parts of ginger, 9 parts of aster, 10 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 5 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (9)

1. A prescription for treating pneumonia infected by novel coronavirus is characterized in that the raw materials comprise the following traditional Chinese medicine materials in parts by weight:
8-10 parts of ephedra, 5-8 parts of honey-fried licorice root, 8-10 parts of almond, 15-30 parts of gypsum, 8-10 parts of cassia twig, 8-10 parts of rhizoma alismatis, 8-10 parts of polyporus umbellatus, 8-10 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 15-18 parts of radix bupleuri, 5-8 parts of scutellaria baicalensis, 8-10 parts of ginger processed pinellia tuber, 8-10 parts of ginger, 8-10 parts of aster, 8-10 parts of flos farfarae, 8-10 parts of blackberry lily, 5-8 parts of asarum, 10-14 parts of Chinese yam, 5-8 parts of immature bitter orange, 5-8 parts of dried orange peel and 8-10 parts of wrinkled gianthys.
2. The prescription according to claim 1, wherein the raw materials comprise the following Chinese medicinal materials in parts by weight:
9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
3. The prescription according to claim 2, wherein the Chinese medicinal raw materials comprise the following Chinese medicinal materials in parts by weight:
9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of gypsum, 9 parts of cassia twig, 9 parts of rhizoma alismatis, 9 parts of grifola, 9 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 16 parts of radix bupleuri, 6 parts of scutellaria baicalensis, 9 parts of ginger processed pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of flos farae, 9 parts of blackberry lily, 6 parts of asarum, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled gianthyssop herb.
4. The formulation of any one of claims 1 to 3, in the form of a decoction.
5. A process for the preparation of a formulation as claimed in any one of claims 1 to 4, wherein the raw materials are decocted with water, wherein gypsum is first decocted and the other ingredients are then added and decocted.
6. Use of a formulation according to any one of claims 1 to 4 for the manufacture of a medicament having lung clearing and detoxifying effects.
7. Use of a formulation according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of pulmonary inflammatory diseases.
8. The use of claim 7, wherein the pneumonia is caused by a viral infection.
9. The use according to claim 8, wherein said viruses include, but are not limited to, novel coronavirus 2019-nCoV, respiratory syndrome coronavirus, and respiratory syncytial virus.
CN202010081961.5A 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof Active CN110870402B (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202010081961.5A CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof
JP2022546454A JP7424684B2 (en) 2020-02-06 2021-01-26 Chinese herbal medicine complex prescription with lung purifying and detoxifying function and its application
CA3168659A CA3168659A1 (en) 2020-02-06 2021-01-26 Traditional chinese medicine compound with lung-clearing and toxin-expelling functions, and application thereof
KR1020227028314A KR20220137663A (en) 2020-02-06 2021-01-26 Chinese medicine complex prescription with detoxification function and its use
PCT/CN2021/073829 WO2021155751A1 (en) 2020-02-06 2021-01-26 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
TW110103119A TWI792162B (en) 2020-02-06 2021-01-27 A compound traditional Chinese medicine with the function of clearing lung and expelling toxin and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010081961.5A CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Publications (2)

Publication Number Publication Date
CN110870402A true CN110870402A (en) 2020-03-06
CN110870402B CN110870402B (en) 2020-07-17

Family

ID=69660088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010081961.5A Active CN110870402B (en) 2020-02-06 2020-02-06 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Country Status (6)

Country Link
JP (1) JP7424684B2 (en)
KR (1) KR20220137663A (en)
CN (1) CN110870402B (en)
CA (1) CA3168659A1 (en)
TW (1) TWI792162B (en)
WO (1) WO2021155751A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110824A (en) * 2020-03-26 2020-05-08 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN111150792A (en) * 2020-03-11 2020-05-15 江苏卫生健康职业学院 Chinese medicinal composition with effect of resisting novel coronavirus SARS-Cov-2, and preparation method and application thereof
CN111154923A (en) * 2020-04-07 2020-05-15 中国医学科学院医学实验动物研究所 Primer for amplifying nucleotide fragment of novel coronavirus (SARS-CoV-2) gene and application thereof
CN111202802A (en) * 2020-04-20 2020-05-29 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Traditional Chinese medicine composition for eliminating dampness and ventilating lung and application thereof
CN111214637A (en) * 2020-03-10 2020-06-02 贵州神奇药物研究院 Traditional Chinese medicine composition and preparation method and medicinal application thereof
CN111228423A (en) * 2020-04-02 2020-06-05 湖南补天药业股份有限公司 Pharmaceutical composition applied to novel rehabilitation and nursing of coronavirus pneumonia
CN111265586A (en) * 2020-03-16 2020-06-12 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111265636A (en) * 2020-03-21 2020-06-12 刘彬 A Chinese medicinal composition for treating malignant infectious diseases and preparation method thereof
CN111349719A (en) * 2020-03-09 2020-06-30 广州医科大学附属第一医院（广州呼吸中心） Specific primer for detecting novel coronavirus and rapid detection method
CN111437370A (en) * 2020-04-15 2020-07-24 李经纬 Traditional Chinese medicine ointment formula applied to viral influenza and processing method thereof
CN111467451A (en) * 2020-05-11 2020-07-31 劲牌持正堂药业有限公司 Composition and preparation for treating novel coronavirus pneumonia and application of composition and preparation
CN111513378A (en) * 2020-04-03 2020-08-11 枣庄学院 Novel coronary pneumonia virus protective clothing for public culture space prevention and treatment
CN111537743A (en) * 2020-04-03 2020-08-14 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111529660A (en) * 2020-04-24 2020-08-14 于明华 Antiviral traditional Chinese medicine
CN111557994A (en) * 2020-04-16 2020-08-21 江西浣星谷科技有限公司 Preparation for preventing and adjuvant treating coronavirus infection and preparation method thereof
CN111643646A (en) * 2020-04-26 2020-09-11 北京国梦中和方略科技研究院 Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof
CN111867412A (en) * 2020-04-03 2020-10-30 枣庄学院 Novel coronary pneumonia virus protective clothing for public culture space prevention and treatment
CN112138133A (en) * 2020-10-23 2020-12-29 成都中医药大学附属医院 Pharmaceutical composition for preventing and/or treating novel coronavirus pneumonia and preparation method and application thereof
CN112515162A (en) * 2020-04-09 2021-03-19 宋交愚 Selenium-enriched additive composition for resisting neocoronarism for areca nuts and preparation method thereof
CN112675282A (en) * 2021-02-02 2021-04-20 王忠兰 Composition for treating pneumonia, preparation method and particles prepared by composition
WO2021155751A1 (en) * 2020-02-06 2021-08-12 中国中医科学院中医临床基础医学研究所 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
CN113332408A (en) * 2021-05-26 2021-09-03 王士红 Lung-clearing and toxin-expelling cigarette
CN113440563A (en) * 2020-03-26 2021-09-28 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
WO2021208334A1 (en) * 2020-04-16 2021-10-21 广东省中医院 Qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and predation method therefor and application thereof
WO2022010424A1 (en) * 2020-07-10 2022-01-13 Kanjanakaroonwong Chaiyaporn Herbal ingredients and manufacturing process for eliminating the coronavirus
CN113952304A (en) * 2021-07-08 2022-01-21 中国中医科学院中医临床基础医学研究所 Lung-clearing and toxin-expelling granules and preparation method thereof
WO2021205083A3 (en) * 2020-04-11 2022-03-10 Finindsutria Srl Composition comprising an antioxidant for the prevention or treatment of covid-19
CN114569652A (en) * 2022-03-22 2022-06-03 深圳市中医院 Traditional Chinese medicine formula of pathogenic-expelling lung-heat-clearing decoction and preparation method thereof
CN115518141A (en) * 2022-05-18 2022-12-27 大连浙香生物科技有限公司 Essential oil for clearing lung and expelling toxin
CN115671191A (en) * 2021-06-25 2023-02-03 牛连贞 Traditional Chinese medicine formula for treating pneumonia

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102526308B1 (en) * 2022-06-23 2023-04-27 한국 한의학 연구원 Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549061A (en) * 2008-04-01 2009-10-07 河北以岭医药研究院有限公司 Medicament for treating bronchitis and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09309836A (en) * 1996-05-22 1997-12-02 Taisho Pharmaceut Co Ltd Liquid preparation for internal use
KR101637013B1 (en) * 2014-03-19 2016-07-08 건국대학교 산학협력단 Compositions for Anti-Influenza Virus Comprising Extract of Poncirus trifoliata as Active Ingredients
CN107875278A (en) * 2017-12-08 2018-04-06 江苏师范大学 A kind of Chinese medicine sachet for deficiency of Yin matter crowd's flu-prevention
CN110870402B (en) * 2020-02-06 2020-07-17 葛又文 Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549061A (en) * 2008-04-01 2009-10-07 河北以岭医药研究院有限公司 Medicament for treating bronchitis and preparation method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
何永明: "柴苓汤方证研究", 《中国博士学位论文全文数据库 医药卫生辑》 *
曙光健康网: "河北省新型冠状病毒感染的肺炎中医治疗方案（试行第三版）", 《HTTPS://WWW.SG120.COM/ZY/19355.HTML》 *
河北中医药: "河北省新型冠状病毒感染的肺炎中医防治方案（试行第三版）", 《河北中医药管理局官方公众号（河北中医药）》 *
河北省卫生健康委员会、河北省中医药管理局: "河北省新型冠状病毒感染的肺炎诊疗方案（试行第二版）", 《河北省中医药管理局官网》、《河北省卫生健康委员会官网》 *
陈红霞: "四个经方及其合方并用对大鼠哮喘模型嗜酸性粒细胞浸润、凋亡及Fas和Bcl-2表达的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021155751A1 (en) * 2020-02-06 2021-08-12 中国中医科学院中医临床基础医学研究所 Traditional chinese medicine compound with functions of clearing lungs and detoxification, and application thereof
CN111349719A (en) * 2020-03-09 2020-06-30 广州医科大学附属第一医院（广州呼吸中心） Specific primer for detecting novel coronavirus and rapid detection method
CN111214637A (en) * 2020-03-10 2020-06-02 贵州神奇药物研究院 Traditional Chinese medicine composition and preparation method and medicinal application thereof
CN111150792A (en) * 2020-03-11 2020-05-15 江苏卫生健康职业学院 Chinese medicinal composition with effect of resisting novel coronavirus SARS-Cov-2, and preparation method and application thereof
CN111265586B (en) * 2020-03-16 2020-10-20 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111265586A (en) * 2020-03-16 2020-06-12 首都医科大学附属北京地坛医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111265636A (en) * 2020-03-21 2020-06-12 刘彬 A Chinese medicinal composition for treating malignant infectious diseases and preparation method thereof
WO2021189753A1 (en) * 2020-03-26 2021-09-30 广东省中医院 Pharmaceutical composition for strengthening body and treating lung diseases and application thereof
CN111110824B (en) * 2020-03-26 2020-07-21 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN113440563A (en) * 2020-03-26 2021-09-28 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
CN113440563B (en) * 2020-03-26 2022-09-06 浙江康恩贝制药股份有限公司 Compound houttuynia cordata spray and preparation method and application thereof
CN111110824A (en) * 2020-03-26 2020-05-08 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CN111228423A (en) * 2020-04-02 2020-06-05 湖南补天药业股份有限公司 Pharmaceutical composition applied to novel rehabilitation and nursing of coronavirus pneumonia
CN111867412A (en) * 2020-04-03 2020-10-30 枣庄学院 Novel coronary pneumonia virus protective clothing for public culture space prevention and treatment
CN111513378A (en) * 2020-04-03 2020-08-11 枣庄学院 Novel coronary pneumonia virus protective clothing for public culture space prevention and treatment
CN111537743B (en) * 2020-04-03 2022-05-03 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111537743A (en) * 2020-04-03 2020-08-14 广州医科大学附属第一医院（广州呼吸中心） SARS-CoV-2 new coronavirus antibody detection reagent kit
CN111154923A (en) * 2020-04-07 2020-05-15 中国医学科学院医学实验动物研究所 Primer for amplifying nucleotide fragment of novel coronavirus (SARS-CoV-2) gene and application thereof
CN112515162A (en) * 2020-04-09 2021-03-19 宋交愚 Selenium-enriched additive composition for resisting neocoronarism for areca nuts and preparation method thereof
WO2021205083A3 (en) * 2020-04-11 2022-03-10 Finindsutria Srl Composition comprising an antioxidant for the prevention or treatment of covid-19
CN111437370A (en) * 2020-04-15 2020-07-24 李经纬 Traditional Chinese medicine ointment formula applied to viral influenza and processing method thereof
CN111557994A (en) * 2020-04-16 2020-08-21 江西浣星谷科技有限公司 Preparation for preventing and adjuvant treating coronavirus infection and preparation method thereof
WO2021208334A1 (en) * 2020-04-16 2021-10-21 广东省中医院 Qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and predation method therefor and application thereof
WO2021212721A1 (en) * 2020-04-20 2021-10-28 广东省中医院 Traditional chinese medicine composition for dispelling dampness and clearing lung and application thereof
CN111202802A (en) * 2020-04-20 2020-05-29 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） Traditional Chinese medicine composition for eliminating dampness and ventilating lung and application thereof
CN111529660A (en) * 2020-04-24 2020-08-14 于明华 Antiviral traditional Chinese medicine
CN111643646A (en) * 2020-04-26 2020-09-11 北京国梦中和方略科技研究院 Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof
CN111467451A (en) * 2020-05-11 2020-07-31 劲牌持正堂药业有限公司 Composition and preparation for treating novel coronavirus pneumonia and application of composition and preparation
WO2022010424A1 (en) * 2020-07-10 2022-01-13 Kanjanakaroonwong Chaiyaporn Herbal ingredients and manufacturing process for eliminating the coronavirus
CN112138133B (en) * 2020-10-23 2021-10-19 成都中医药大学附属医院 Pharmaceutical composition for treating novel coronavirus pneumonia and preparation method and application thereof
CN112138133A (en) * 2020-10-23 2020-12-29 成都中医药大学附属医院 Pharmaceutical composition for preventing and/or treating novel coronavirus pneumonia and preparation method and application thereof
CN112675282A (en) * 2021-02-02 2021-04-20 王忠兰 Composition for treating pneumonia, preparation method and particles prepared by composition
CN113332408A (en) * 2021-05-26 2021-09-03 王士红 Lung-clearing and toxin-expelling cigarette
CN115671191A (en) * 2021-06-25 2023-02-03 牛连贞 Traditional Chinese medicine formula for treating pneumonia
CN113952304A (en) * 2021-07-08 2022-01-21 中国中医科学院中医临床基础医学研究所 Lung-clearing and toxin-expelling granules and preparation method thereof
CN114569652A (en) * 2022-03-22 2022-06-03 深圳市中医院 Traditional Chinese medicine formula of pathogenic-expelling lung-heat-clearing decoction and preparation method thereof
CN115518141A (en) * 2022-05-18 2022-12-27 大连浙香生物科技有限公司 Essential oil for clearing lung and expelling toxin

Also Published As

Publication number Publication date
JP7424684B2 (en) 2024-01-30
JP2023512529A (en) 2023-03-27
KR20220137663A (en) 2022-10-12
TWI792162B (en) 2023-02-11
CA3168659A1 (en) 2021-08-12
WO2021155751A1 (en) 2021-08-12
CN110870402B (en) 2020-07-17
TW202140053A (en) 2021-11-01

Similar Documents

Publication Publication Date Title
CN110870402B (en) Traditional Chinese medicine compound for treating pneumonia caused by novel coronavirus infection and application thereof
CN101461911B (en) Chinese medicine oral capsule for treating gout
CN111388582B (en) Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof
CN104173704A (en) Traditional Chinese medicine decoction for treating subacute thyroiditis
CN101143176A (en) Traditional Chinese medicine for treating pneumonia
CN111773308A (en) Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method
CN111110819A (en) Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza
CN116139237B (en) A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application
CN111991480A (en) Traditional Chinese medicine composition for preventing novel coronavirus pneumonia infection
CN101664524A (en) Medicament for treating paranasal sinusitis and preparation method thereof
CN111840456A (en) Chinese medicinal composition for treating respiratory system diseases
CN101293073B (en) Chinese medicinal composition for treating systematic lupus erythematosus
CN105194584A (en) Medicine for treating dysmenorrhea
CN104096053A (en) Medicine composition for treating infantile pneumonia
CN111228366B (en) Traditional Chinese medicine composition for treating viral pneumonia
CN103860786A (en) Medicine for treating puerperal fever
CN111375036B (en) Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN102048871A (en) Formula of traditional Chinese medicine for treating renal calculus
CN100393345C (en) Oral preparation for treating gynecopathy
CN106237014A (en) A kind of Chinese medicine composition treating chronic nephritis
CN106236971A (en) A kind of Chinese medicine composition treating chronic nephritis
CN101327283B (en) Composite medicine for treating nephrosis and its preparing process
CN106177250A (en) A kind of Chinese medicine composition treating chronic nephritis
CN101143194A (en) Traditional Chinese medicine for treating interstitial pneumonia
CN105169009A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating viral influenza

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026270

Country of ref document: HK